Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.30 |
| ▸ | WNT3A | P56704 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27042972 | 0.81 | ALDH1A1 (0.33) | MEN1KMT2AHTTGSK3BPOLB | |
| SCHEMBL286718 | 0.74 | HAAO (0.42) | MEN1KMT2ANCEH1 | |
| SCHEMBL12544237 | 0.72 | SIRT3 (0.41) | KMT2AHTTNCEH1 | |
| SCHEMBL5459335 | 0.71 | LMNA (0.48) | MEN1KMT2AHTTCTNNB1WNT3A | |
| SCHEMBL12860312 | 0.71 | CTNNB1 (0.56) | MEN1KMT2ACTNNB1WNT3A | |
| SCHEMBL11620648 | 0.70 | MEN1 (0.38) | MEN1KMT2AHTTGSK3B | |
| SCHEMBL20554833 | 0.70 | SHBG (0.55) | MEN1KMT2AHTTGAA | |
| SCHEMBL20554676 | 0.70 | PIK3CA (0.40) | MEN1KMT2AHTT | |
| SCHEMBL30132562 | 0.70 | SHBG (0.55) | MEN1KMT2AHTTGAA | |
| SCHEMBL26607361 | 0.70 | MEN1 (0.38) | MEN1KMT2AHTTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633252-B2 | Use of pterosin compounds for treating diabetes and obesity | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-01-21 | — | — | US | disclosed |
| US-8633252-B2 | Use of pterosin compounds for treating diabetes and obesity | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-01-21 | — | — | US | disclosed |
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | US | disclosed |
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | US | disclosed |
| US-6300376-B1 | FOR THERAPY TO ACHIEVE SMOOTH MUSCLE RELAXING ACTIVITY AND/OR MAST CELL STABILIZING ACTIVITY AND/OR ANTI-INFLAMMATORY ACTIVITY | VENANTIUS LIMITED (IR) | 2001-10-09 | — | — | US | disclosed |
| EP-0865419-A1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | Venantius Limited (IE) | 1998-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | PGC, PTMA, GPR119 | MEN1 2040/4885KMT2A 1725/4885HTT 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.